Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

16.83 +0.46 (+2.81%)
Streaming Delayed Price Updated: 12:04 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acadia Pharmaceutica

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
3 Biotech Stocks With the Strongest Clinical Pipelines
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines. 
Via InvestorPlace
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Why Acadia Pharmaceuticals Stock Is Rising Today
An analyst upgrade is sparking a rally in the drugmaker's shares today. 
Via The Motley Fool
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
2 Growth Stocks I'd Buy on the Dip
These two growth stocks could be worthwhile buy-and-holds. 
Via The Motley Fool
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?
This biotech stock has been on fire in 2023. 
Via The Motley Fool
Analyst Expectations for ACADIA Pharmaceuticals's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Via Benzinga
Electronic Arts To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Tuesday
JP Morgan increased ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) price target from $29 to $32. JP Morgan analyst Tessa Romero upgraded the stock from Neutral to Overweight. ACADIA Pharmaceuticals shares... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant... 
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
2 Supercharged Growth Stocks Billionaires Can't Stop Buying
A top hedge fund has been steadily buying these two growth stocks in 2023. 
Via The Motley Fool
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
This small-cap biotech might be a hidden gem. 
Via The Motley Fool
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
JP Morgan Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.